As Chinese equities show mixed performance amid weak manufacturing data, investors are increasingly focused on identifying growth opportunities in the region. Companies with high insider ownership often signal confidence from those closest to the business, making them attractive candidates for potential investment.
Top 10 Growth Companies With High Insider Ownership In China
| Name | Insider Ownership | Earnings Growth |
| Ningbo Sunrise Elc TechnologyLtd (SZSE:002937) | 24.3% | 27.7% |
| ShenZhen Woer Heat-Shrinkable MaterialLtd (SZSE:002130) | 19% | 27.9% |
| Suzhou Shijing Environmental TechnologyLtd (SZSE:301030) | 22% | 54.9% |
| Arctech Solar Holding (SHSE:688408) | 38.7% | 28.4% |
| Cubic Sensor and InstrumentLtd (SHSE:688665) | 10.1% | 34.3% |
| KEBODA TECHNOLOGY (SHSE:603786) | 12.8% | 25.1% |
| Suzhou Sunmun Technology (SZSE:300522) | 36.5% | 63.4% |
| Eoptolink Technology (SZSE:300502) | 26.7% | 39.4% |
| Sineng ElectricLtd (SZSE:300827) | 36.5% | 39.8% |
| UTour Group (SZSE:002707) | 23% | 36.1% |
Underneath we present a selection of stocks filtered out by our screen.
Asia Cuanon Technology (Shanghai)Ltd (SHSE:603378)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Asia Cuanon Technology (Shanghai) Ltd (SHSE:603378) operates in the construction materials industry and has a market cap of CN¥3.13 billion.
Operations: Asia Cuanon Technology (Shanghai) Ltd (SHSE:603378) operates in the construction materials industry and has a market cap of CN¥3.13 billion. The company generates revenue from various segments, contributing to its overall financial performance.
Insider Ownership: 15.4%
Asia Cuanon Technology (Shanghai) Ltd. has shown significant growth potential with earnings forecasted to grow 61.29% per year, outpacing the Chinese market's revenue growth rate of 13.6%. Despite a volatile share price and an unstable dividend track record, the company completed a buyback of 7,902,989 shares for CNY 50.01 million in May 2024, indicating confidence from management. However, its return on equity is projected to be low at 10.9% in three years and interest payments are not well covered by earnings.
- Click here to discover the nuances of Asia Cuanon Technology (Shanghai)Ltd with our detailed analytical future growth report.
- Our comprehensive valuation report raises the possibility that Asia Cuanon Technology (Shanghai)Ltd is priced lower than what may be justified by its financials.
Bio-Thera Solutions (SHSE:688177)
Simply Wall St Growth Rating: ★★★★★★
Overview: Bio-Thera Solutions, Ltd. is a biopharmaceutical company focused on researching and developing novel therapeutics for treating cancer, autoimmune, cardiovascular, and other serious medical conditions, with a market cap of CN¥8.91 billion.
Operations: Revenue from biopharmaceuticals for Bio-Thera Solutions, Ltd. amounted to CN¥711.46 million.
Insider Ownership: 18.2%
Bio-Thera Solutions, a growth company with high insider ownership, has recently gained EMA approval for BAT1706 (bevacizumab), marketed as Avzivi® in Europe by Sandoz AG. The company's earnings have grown 20.8% annually over the past five years and are forecasted to grow 27.9% per year, outpacing the Chinese market's average growth rate of 13.6%. Despite a volatile share price and less than one year of cash runway, Bio-Thera is expected to become profitable within three years with an impressive return on equity forecasted at 34.5%.
- Click here and access our complete growth analysis report to understand the dynamics of Bio-Thera Solutions.
- Our valuation report unveils the possibility Bio-Thera Solutions' shares may be trading at a premium.
Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHSE:688266) is a biopharmaceutical company with a market cap of CN¥13.97 billion, focusing on the development and commercialization of innovative drugs.
Operations: The company's revenue primarily comes from its pharmaceuticals segment, which generated CN¥386.57 million.
Insider Ownership: 29.4%
Suzhou Zelgen Biopharmaceuticals Ltd. is expected to see substantial revenue growth at 55.7% per year, significantly outpacing the Chinese market's average of 13.6%. Although its return on equity is forecasted to be low at 9.6% in three years, the company is trading at a considerable discount of 73.8% below its estimated fair value and is projected to become profitable within the next three years, demonstrating above-average market growth potential.
- Unlock comprehensive insights into our analysis of Suzhou Zelgen BiopharmaceuticalsLtd stock in this growth report.
- Our expertly prepared valuation report Suzhou Zelgen BiopharmaceuticalsLtd implies its share price may be too high.
Turning Ideas Into Actions
- Unlock more gems! Our Fast Growing Chinese Companies With High Insider Ownership screener has unearthed 355 more companies for you to explore.Click here to unveil our expertly curated list of 358 Fast Growing Chinese Companies With High Insider Ownership.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SHSE:603378
Asia Cuanon Technology (Shanghai)Ltd
Asia Cuanon Technology (Shanghai) Co.,Ltd.
Reasonable growth potential and fair value.
